https://mik665inhibitor.com/af....tereffect-of-a-fourt
TECHNIQUES We carried out a systematic analysis and chosen studies (2004-2019) reporting information concerning the management of allogeneic MSC when it comes to prevention (n = 654 customers) or remedy for intense (letter = 943 customers) or persistent (n = 76 patients) GvHD after HSCT. Our main outcome ended up being overall survival during the final folsponse was 66% (95% CI, 0.55-0.76) and was total in 23% (95% CI 0.12-0.34) of clients. CONCLUSIONS Our meta-analysis indica
Like
Comment
Share
